3 Branded Generics and Contract Manufacturing Company, Artificial Leather Maker and Pharma Formulations Company Stocks With a Strong Future Roadmap: Innova Captab, Mayur Uniquoters and Granules India

Generic, synthetic leather and drug stocks let investors follow companies that serve a growing part of the Indian economy. Innova Captab, Mayur Uniquoters and Granules India cover a branded generics and contract manufacturing company, an artificial leather maker and a pharma intermediates and formulations company.

This list covers three generic, synthetic leather and drug stocks with complete current figures: Innova Captab, Mayur Uniquoters and Granules India. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic, Synthetic Leather and Drug Stocks?

Generic, synthetic leather and drug stocks are listed companies that make branded generics and manufacture for other drug brands, produce artificial leather for auto upholstery, furniture and footwear and supply intermediates and finished dosage forms to global customers. Their earnings depend on export orders, approvals and product mix.

Generic, Synthetic Leather and Drug Stocks at a Glance

On valuation, Mayur Uniquoters and Granules India trade at a P/E below the industry P/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing generic, synthetic leather and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic, synthetic leather and drug stocks can use the coming numbers to test whether growth is holding.

Why Do Generic, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?

Generic, synthetic leather and drug stocks have a strong roadmap in India because steady medicine demand, vehicle makers using more synthetic upholstery and global buyers adding Indian suppliers keep widening the market for these export focused makers.

• Contract work. Drug brands outsource manufacturing.
• Material demand. Vehicles and furniture use artificial leather.
• Global buyers. Overseas customers add Indian partners.

Why Innova Captab Features Among These Generic, Synthetic Leather and Drug Stocks

Among the generic, synthetic leather and drug stocks on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Why Mayur Uniquoters Features Among These Generic, Synthetic Leather and Drug Stocks

Among the pharma and material exporters shares on this list, Mayur Uniquoters is a Rajasthan-based maker of artificial leather and synthetic fabrics used in footwear, automotive upholstery, furniture and other applications.

The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9.

Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore.

Roadmap: The company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

What to watch: Check the volume trend in automotive and footwear customers and export sales.

Why Granules India Features Among These Generic, Synthetic Leather and Drug Stocks

Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Innova Captab vs Mayur Uniquoters vs Granules India on Key Financials

The table below sets the three generic, synthetic leather and drug stocks side by side on revenue, profit and margin, using reported figures.

Mayur Uniquoters posts the highest return on equity in this group at 16.9%. Granules India has the largest FY26 revenue at Rs 5,386 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with generic, synthetic leather and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several export oriented pharma and materials stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Generic, Synthetic Leather and Drug Stocks

Every theme carries risks that deserve a check before any decision. For these generic, synthetic leather and drug stocks, the main points are: Long-term pharma and material exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter generic, synthetic leather and drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Generic, Synthetic Leather and Drug Stocks

Generic, synthetic leather and drug stocks reward investors who follow demand trends, order books and margins together. Innova Captab, Mayur Uniquoters and Granules India each have a clear plan to grow. Based on the 29 October 2026 close, Innova Captab trades at Rs 1,051.1, Mayur Uniquoters at Rs 722.85 and Granules India at Rs 837.35. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generic, synthetic leather and drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track generic, synthetic leather and drug stocks, set price alerts and get research-backed stock ideas.

What are generic, synthetic leather and drug stocks?

Ans. Generic, synthetic leather and drug stocks are listed companies that make branded generics and manufacture for other drug brands, produce artificial leather for auto upholstery, furniture and footwear and supply intermediates and finished dosage forms to global customers. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Innova Captab, Mayur Uniquoters and Granules India, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which generic, synthetic leather and drug stocks are covered in this list?

Ans. This list covers Innova Captab, Mayur Uniquoters and Granules India. Based on the 29 October 2026 close, Innova Captab traded at Rs 1,051.1, Mayur Uniquoters at Rs 722.85 and Granules India at Rs 837.35. Their return on equity ranges from 11.7% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.5%.

Why do generic, synthetic leather and drug stocks have a strong future roadmap in India?

Ans. Generic, synthetic leather and drug stocks have a strong roadmap in India because steady medicine demand, vehicle makers using more synthetic upholstery and global buyers adding Indian suppliers keep widening the market for these export focused makers. The main drivers are as follows. Contract work. Drug brands outsource manufacturing. Material demand. Vehicles and furniture use artificial leather. Global buyers. Overseas customers add Indian partners. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

How has Mayur Uniquoters performed financially?

Ans. Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What risks should investors check before buying generic, synthetic leather and drug stocks?

Ans. Investors should check a few risks before buying generic, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of generic, synthetic leather and drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.